title: Influence of piperine and quercetin on antidiabetic potential of curcumin.
abstract: BACKGROUND
  Curcumin is a nutraceutical obtained from the rhizomes of Curcuma longa with a significant medicinal value against numerous disorders. However, the potential cannot be completely exploited due to low in vivo bioavailability. Hence, in order to enhance the bioavailability of curcumin, we combined it with the bioavailability enhancers like piperine and quercetin.
  
  
  METHODS
  The present study was targeted to explore the antidiabetic potential of combinatorial extract of curcumin with piperine and quercetin (CPQ) in streptozotocin- and nicotinamide-induced diabetic rats. Diabetes mellitus was induced by single intraperitoneal injection of streptozotocin (55 mg/kg) and nicotinamide (120 mg/kg-1). CPQ was orally administered at 100 mg kg-1 dose/day for a period of 28 days. At the end of 28 days, blood was analyzed for glucose, high density lipoprotein (HDL), low density lipoprotein (LDL) and total cholesterol level. Oral glucose tolerance test (OGTT) was also conducted at the end of 28 days.
  
  
  RESULTS
  Oral administration of CPQ at the dose of 100 mg kg-1 significantly (p<0.01) reduced plasma glucose at the end of 28 days, as compared to the diabetic control group. The reduction in the plasma glucose produced by the CPQ extract was equivalent to that of glibenclamide and significantly more compared to curcumin alone (p<0.01). Furthermore, a significant (p<0.01) reduction in the raised LDL, cholesterol and triglycerides and improvement was observed in the group fed with CPQ compared to diabetic control as well as the alone (p<0.05) curcumin group. There was a significant improvement in the body weight with CPQ compared to diabetes control group. OGTT revealed a significantly high glucose tolerance in CPQ fed rats compared to the diabetic control as well as the rats fed with curcumin alone.
  
  
  CONCLUSIONS
  Treatment with combinatorial extract of curcumin presented a significantly better therapeutic potential when compared with curcumin alone, which reveals that CPQ, with reduced dose of curcumin may serve as a therapeutic agent in the treatment of type 2 diabetes mellitus.
authors.forename: Ginpreet
authors.initials: G
authors.lastname: Kaur
authors.forename: Mihir
authors.initials: M
authors.lastname: Invally
authors.forename: Meena
authors.initials: M
authors.lastname: Chintamaneni
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D052117:Benzodioxoles / Q000494:pharmacology*; D001682:Biological Availability; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D030024:Curcuma / Q000737:chemistry; D003474:Curcumin / Q000494:pharmacology* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D008517:Phytotherapy; D010880:Piperidines / Q000494:pharmacology*; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D011794:Quercetin / Q000494:pharmacology*; D017208:Rats, Wistar
chemical_list: D000470:Alkaloids; D052117:Benzodioxoles; D001786:Blood Glucose; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D008055:Lipids; D010880:Piperidines; D010936:Plant Extracts; D053284:Polyunsaturated Alkamides; D011794:Quercetin; D003474:Curcumin; C008922:piperine